Profile data is unavailable for this security.
About the company
Aoti, Inc. is engaged in wound care technology around the world. The Company is focused on helping all people with chronic conditions get back to living their lives to the fullest. It does this by enhancing access to care, improving clinical outcomes and quality of life, and advancing health equity. Its products are built with integrity and backed by robust clinical evidence, ensuring safety and efficacy for its patients. Its solutions include Topical Wound Oxygen (TWO2) and NEXA Negative Pressure Wound Therapy (NPWT). TWO2 therapy is a multi-modality patient-administered therapy. TWO2 is a clinically proven therapy for the treatment of chronic and difficult-to-heal wounds. The NEXA NPWT System is a multi-week, multi-patient, disposable system that delivers the performance and flexibility of traditional NPWT systems. TWO2 therapy solutions include TWO2 Extremity Chamber and TWO2 Multi-Patch.
- Revenue in GBP (TTM)37.87m
- Net income in GBP-7.18m
- Incorporated2008
- Employees80.00
- LocationAoti Inc3512 Seagate Way, Suite 100OCEANSIDE 92056United StatesUSA
- Phone+1 (760) 431-4700
- Fax+1 (760) 683-3063
- Websitehttps://aotinc.net/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tissue Regenix Group PLC | 24.37m | -843.81k | 38.44m | 76.00 | -- | 1.67 | 1,319.95 | 1.58 | -0.012 | -0.012 | 0.3455 | 0.3225 | 0.7061 | 1.33 | 6.41 | 320,647.70 | -2.17 | -13.45 | -2.43 | -14.78 | 49.48 | 45.90 | -3.08 | -28.80 | 1.47 | 0.3716 | 0.263 | -- | 20.50 | 13.75 | 36.44 | -- | 9.78 | -- |
| SDI Group PLC | 65.85m | 4.23m | 53.84m | 503.00 | 12.81 | 1.19 | 6.54 | 0.8177 | 0.0402 | 0.0402 | 0.6256 | 0.4344 | 0.793 | 0.989 | 5.34 | 130,906.60 | 5.12 | 7.85 | 6.11 | 10.01 | 30.84 | 64.06 | 6.46 | 9.48 | 1.35 | 4.85 | 0.321 | 0.00 | -2.56 | 30.46 | 9.30 | 17.22 | 12.08 | -- |
| Inspecs Group PLC | 195.14m | -4.11m | 57.44m | 1.67k | -- | 0.5635 | 6.75 | 0.2944 | -0.0404 | -0.0404 | 1.92 | 1.00 | 0.8667 | 2.31 | 7.65 | 116,640.80 | -1.82 | -1.48 | -2.62 | -2.15 | 51.46 | 48.50 | -2.10 | -1.97 | 0.8696 | 0.6441 | 0.377 | -- | 1.16 | 36.45 | 84.22 | -- | 51.04 | -- |
| Creo Medical Group PLC | 30.30m | -22.40m | 73.26m | 278.00 | -- | 1.54 | -- | 2.42 | -0.0629 | -0.0629 | 0.0852 | 0.1311 | 0.3835 | 1.85 | 3.33 | 105,574.90 | -28.35 | -26.07 | -32.89 | -30.94 | 49.50 | 47.58 | -73.93 | -118.24 | 2.38 | -- | 0.2305 | -- | 13.36 | -- | 19.44 | -- | -- | -- |
| EKF Diagnostics Holdings PLC | 50.95m | 4.78m | 132.26m | 309.00 | 27.71 | 1.92 | 13.23 | 2.60 | 0.0105 | 0.0105 | 0.1123 | 0.1516 | 0.6307 | 3.01 | 6.99 | 160,728.70 | 6.34 | 5.20 | 7.35 | 6.13 | 48.05 | 50.04 | 10.05 | 7.91 | 3.08 | 1,703.50 | 0.0175 | 113.68 | -21.05 | 4.34 | 123.28 | -25.30 | 30.37 | -- |
| Aoti Inc | 37.87m | -7.18m | 140.52m | 80.00 | -- | 11.96 | -- | 3.71 | -0.0675 | -0.0675 | 0.356 | 0.1105 | 1.56 | 3.57 | 8.18 | 315,573.40 | -29.55 | -- | -41.81 | -- | 85.76 | -- | -18.96 | -- | 2.57 | -3.08 | 0.4812 | -- | 31.06 | -- | -191.92 | -- | -- | -- |
| Tristel Plc | 39.49m | 6.04m | 188.22m | 213.00 | 31.44 | 6.01 | 22.00 | 4.77 | 0.1256 | 0.1256 | 0.8219 | 0.6567 | 0.992 | 1.51 | 6.26 | 185,394.40 | 15.17 | 8.86 | 17.10 | 10.24 | 82.59 | 80.63 | 15.29 | 10.63 | 3.93 | 411.73 | 0.1605 | 109.99 | 15.70 | 10.14 | 351.98 | 6.40 | 9.88 | 18.05 |
| Advanced Medical Solutions Group plc | 131.11m | 11.13m | 459.45m | 1.50k | 41.36 | 1.89 | 20.46 | 3.50 | 0.051 | 0.051 | 0.6011 | 1.12 | 0.3977 | 1.70 | 4.91 | 154,244.70 | 3.38 | 6.54 | 3.64 | 7.06 | 54.45 | 56.75 | 8.49 | 14.82 | 6.80 | -- | 0.2702 | 25.85 | 1.51 | 4.23 | -22.14 | -6.71 | 15.66 | 12.32 |
| Holder | Shares | % Held |
|---|---|---|
| Royal London Asset Management Ltd.as of 30 Jun 2024 | 2.42m | 2.28% |
| Wasatch Advisors LPas of 30 Jun 2024 | 1.80m | 1.69% |
| Fondita Fund Management Co. Ltd.as of 31 Aug 2024 | 1.14m | 1.07% |
| Octopus Investments Ltd.as of 30 Sep 2024 | 1.01m | 0.95% |
| Premier Fund Managers Ltd.as of 30 Jun 2024 | 878.79k | 0.83% |
| Ninety One UK Ltd.as of 30 Jun 2024 | 757.58k | 0.71% |
| Cooke & Bieler LPas of 28 Jun 2024 | 401.04k | 0.38% |
| Grandeur Peak Global Advisors LLCas of 31 Jul 2024 | 212.35k | 0.20% |
| R.C. Brown Investment Management Plcas of 30 Sep 2024 | 85.00k | 0.08% |
